Actively Recruiting
Investigation of BG-C0979 Safety and Activity With or Without Tislelizumab in Adults Having Selected Advanced Solid Tumors
Led by BeOne Medicines · Updated on 2026-09-28
84
Participants Needed
18
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and early antitumor activity of the drug BG-C0979 alone or combined with tislelizumab in adults with certain advanced solid tumors. This first-in-human study includes Phase 1a, focusing on dose escalation and safety expansion, and Phase 1b, which involves dose optimization and expansion. The study is sponsored by BeOne Medicines and aims to find safe and effective doses for future research. Participants will receive BG-C0979 through intravenous infusion. In Phase 1a, doses are gradually increased to find safe levels, followed by safety expansion at selected doses. In Phase 1b, participants receive optimized doses of BG-C0979 alone or in combination with tislelizumab for selected tumor types. The study includes multiple treatment groups, each with specific dosing plans and evaluation periods lasting up to approximately 24 months. During the study, participants will undergo regular assessments including imaging to measure tumor response, laboratory tests, and monitoring of side effects. Researchers will track drug levels in blood and evaluate measures like overall response rate, duration of response, disease control rate, and progression-free survival. This comprehensive monitoring will continue for up to two years to evaluate safety and preliminary effectiveness of the treatments.
CONDITIONS
Brief Title
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here